Pain, Hope, and Science Collide as Athletes Turn to Magic Mushrooms
By Markian Hawryluk and Kevin Van Valkenburg, ESPN
A group of former professional athletes traveled to Jamaica to try psychedelics as a way to help cope with the aftereffects of concussions and a career of body-pounding injuries. Will this still largely untested treatment work?
US Officials Want to End the HIV Epidemic by 2030. Many Stakeholders Think They Won’t.
By Daniel Chang and Sam Whitehead
The federal government’s ambitious plan to end the HIV epidemic, launched in 2019, has generated new ways to reach at-risk populations in targeted communities across the South. But health officials, advocates, and people living with HIV worry significant headwinds will keep the program from reaching its goals.
UC Physician Training Program Adds Diversity, but Where Do Graduates End Up?
By Stephanie Stephens
Researchers found that, while a University of California medical training program has diversified the system’s pool of medical students, there’s not enough long-term data to know whether graduates return to practice where they’re needed most.
El dolor, la esperanza y la ciencia chocan cuando los atletas recurren a los hongos mágicos
By Markian Hawryluk and Kevin Van Valkenburg, ESPN
El uso de hongos psicodélicos está ganando terreno en los Estados Unidos. Investigadores predicen que la FDA aprobará un tratamiento psicodélico en los próximos cinco años.
¿Se podrá cumplir con la meta de terminar con la epidemia de VIH para 2030?
By Daniel Chang and Sam Whitehead
Debido a las interrupciones de la pandemia, los funcionarios federales no han tenido estimaciones sólidas de nuevas infecciones o el número de personas que viven con VIH desde finales de 2019.
Programa forma médicos multiculturales, pero no siempre ejercen en áreas vulnerables
By Stephanie Stephens
Investigadores han descubierto que el programa ha logrado diversificar la inscripción, pero no hay suficiente seguimiento a largo plazo para saber si estos graduados ejercen en las regiones donde más se necesitan.
Daily Edition for Friday, April 21, 2023
A covid outbreak, the Arcturus variant, fentanyl legislation, abortion pills, med school rankings, insulin costs, and more are in the news.
Tension Builds in Transgender Policy Debate in Montana
By Keely Larson
Two transgender lawmakers are trying to lay the groundwork for LGBTQ-friendly policies in a conservative state, but tensions are running high as the legislative session nears its end.
The Biden Administration Vowed to Be a Leading Voice on Opioid Settlements But Has Gone Quiet
By Aneri Pattani
Billions of dollars are headed to state and local governments to address the opioid crisis. Policy experts and advocates expect the federal government to play a role in overseeing the use of the money. Failure to do so, they say, could lead to wasted opportunities. And, since Medicaid helps pay health care costs, the feds could have a claim to portions of states’ opioid settlements.
KFF Health News' 'What the Health?': Will They or Won’t They (Block the Abortion Pill)?
The Supreme Court is considering the future of the abortion pill mifepristone, after GenBioPro sued the FDA over limitations that effectively block generic production of the drug, a major part of the market. Congress is considering proposals that would impose Medicaid work requirements, crack down on pharmacy benefit managers, and more. And President Joe Biden moved to expand health coverage to young immigrants known as “Dreamers.” Rachel Cohrs of Stat, Sandhya Raman of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KFF Health News’ Mary Agnes Carey to discuss these issues and more.
